Some medications change the chemistry of urine without the person ever noticing. Topiramate — prescribed for migraines, seizures, and increasingly for weight management — is one of them. It works partly by inhibiting an enzyme called carbonic anhydrase, and that same action is what tilts urine chemistry toward stone formation. A large new analysis puts the size of the effect in perspective.
Carbonic anhydrase inhibitors raise urine pH and lower urinary citrate. Citrate is one of the body's natural crystal inhibitors — it binds calcium and blocks crystal growth — so losing it removes a key defense. A 2006 study measured the change directly: urinary citrate fell from about 737 mg/day to 278 mg/day after topiramate treatment, and the saturation ratio for calcium phosphate (brushite) more than doubled. The result is a urine profile that favors calcium phosphate stones, which is why the stone type seen with these drugs is often phosphate-based rather than the more common calcium oxalate.
The practical consequence is a shift in how stone formers on this medication should be monitored. Urine pH runs higher, citrate runs lower, and the usual "drink more water" advice still applies but may not be enough on its own. Some clinicians consider urine alkalinization or citrate supplements — but every one of those decisions belongs to the prescribing physician.
While medication changes urine chemistry, food still sets the baseline. For someone on topiramate, the low-oxalate foods matter more, not less:
| Food | Oxalate (mg) | Serving | Rating |
|---|---|---|---|
| Water, still | 0 mg | 1 glass | Safe |
| Chicken breast, roasted | 0 mg | 4 oz | Safe |
| Salmon, cooked | 0 mg | 4 oz | Safe |
| Banana | 6 mg | 1 medium | Safe |
| Apple, fresh | 2 mg | 1 medium | Safe |
These foods carry little or no oxalate, which keeps the dietary side of the ledger clean. The dietary pattern for topiramate users is otherwise the same as for any stone former: generous fluids, moderate sodium, adequate dietary calcium, and the high-oxalate foods portioned rather than central.
For anyone starting topiramate or already on it: know the mechanism, ask your doctor whether stone risk monitoring makes sense for you, and do not read this page as a stop-medication signal. The data say the association is real and dose- and indication-dependent — not that every user forms a stone. A person with a stone history starting this drug has a different risk profile than someone with no stone history, and that difference is exactly what a prescribing conversation is for.
See how oxalate values are measured and verified on our data methodology page.